DKSH has entered into an exclusive partnership with R-Biomeds, an emerging healthcare company with a vision to lead the healthcare market and build trust in the world of pharmaceuticals. Together, they will bring the necessary medication to patients in Cambodia.
Cambodia, Phnom Penh, October 8, 2024 - DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia and beyond, has signed an exclusive agreement with R-Biomeds, a global pharmaceutical company based in Singapore. As part of this exclusive partnership, DKSH will expand R-Biomeds‘s range of pharmaceuticals, including Oncology, Bio-similars, and Thyroid medicines, to the Cambodian market.
As a strategic partner, DKSH has been collaborating with R-Biomeds to drive growth in Myanmar and, with great success, is now expanding the partnership in Cambodia. DKSH Cambodia will help R-Biomeds grow its business, solidify its brand presence, and gain market share by managing R-Biomeds's distribution and logistics, marketing, and sales. Its experienced teams and broad distribution network will ensure that its products reach modern and traditional trade, hospitals, clinics, other medical channels, and patients in need nationwide.
Rajeev Rawal, Managing Director of R-Biomeds, commented: “We are delighted to partner with DKSH to bring our high-quality medicines to patients in Cambodia. We are confident in DKSH's strong nation-wide footprint, extensive distribution network, and expertise to further strengthen R-Biomeds's brands and growth in this market.”
Philip Wray, Vice President of Healthcare at DKSH in Cambodia, said: “With our expertise in Market Expansion Services, we are proud to be R-Biomeds’s trusted and strategic partner. Our partnership demonstrates our commitment to providing patients with better health and quality of life, in line with DKSH's purpose to enrich people's lives and our mission of healthcare for all.”.
About R-Biomeds
R-Biomeds, Singapore, is an emerging healthcare company with a vision to lead the healthcare market and build trust in the world of pharmaceuticals. The company was incorporated with the goal of supporting various verticals in the medical field and building a reputable brand across South Asia. www.rbiomeds.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, the Business Unit generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec